Co-creating Value with Stakeholders

To realize our Vision for Kyowa Kirin, we need to create both social and economic value. An essential part of this process is cooperating and collaborating with stakeholders in the value chain. We are committed to mutual understanding and deepening our relationship with stakeholders through various communication opportunities.

Our Key Stakeholders and Communication Opportunities

Stakeholders. People facing illness: Patients, caregivers, patient communities、Healthcare professionals. Employees: Employees. Business partners: Partners (suppliers, pharmaceutical wholesalers, etc.), Joint R&D partners. Capital providers: Shareholders / investors. Policymakers, industry associations: Industry associations, Central and local governments, Regulators / payers. Community, Environment: Communities, Future generations / environment

You can see this table by scrolling horizontally.

Stakeholders	Main communication opportunities and frequency
Patients, caregivers, patient communities	Disease and health information websites	Ongoing
	Medical information contact center	Ongoing
	Patient advocacy activities	Ongoing
Healthcare professionals	Medical websites	Ongoing
	Medical information contact center	Ongoing
	Publication of medical findings in journals and at conferences	Ongoing
	Communication via MR/MSL	Ongoing
Employees	Internal intranet	Ongoing
	Whistleblowing system^*1	Ongoing
	Awards for employees	1 time
	Employee engagement survey	1 time
	Interviews with superiors and team members	Ongoing
	Labor-management talks	Ongoing
Partners (Suppliers, pharmaceutical wholesalers, etc.)	Supplier briefings	1 time
	Sustainable procurement questionnaire	1 time
	Collaboration on business transactions	Ongoing
Joint R&D partners	Partnerships in pharmaceutical research and development	Ongoing
Shareholders / investors	General meeting of shareholders	1 time
	Financial results briefings	4 times
	IR events for R&D and ESG topics	3 times
	President IR interviews	25 times
	IR interviews by senior managers	31 times
	IR interviews by IR staff	132 times
Industry associations, central and local governments, regulators / payers	Advocacy and collaboration through industry bodies	Ongoing
Communities	Initiatives to support communities	Ongoing
Communities	Dialogue with local residents	Ongoing
Future generations / environment	Initiatives to support communities	Ongoing
Future generations / environment	Climate change response and other environmental measures	Ongoing

*1
The Company has also established a whistleblower system for stakeholders as part of its grievance mechanism.

Initiatives and Industry Associations

Through our involvement in initiatives and industry associations, we understand the demands of our stakeholders and apply them to our group's business activities. In addition, through collaboration with initiatives and industry associations, we will address social issues that are difficult for individual companies to resolve on their own.

Initiatives

Participation as Kyowa Kirin: Task Force on Climate-related Financial Disclosures (TCFD)

World Anti Doping Agency (WADA)

Pharmaceutical Supply Chain Initiative (PSCI)
Participation as the Kirin Group: The United Nations Global Compact^*

RE100

Science Based Targets initiative (SBTi)

*
The Kirin Group, to which our Group belongs, has announced participation in the United Nations Global Compact since September 2005. As a member of the Kirin Group, we observe the 10 principles of the United Nations Global Compact, which address human rights, labor, the environment, and anticorruption

Industry Associations

Japan Business Federation
FPMAJ (The Federation of Pharmaceutical Manufacturers' Associations of JAPAN)
JPMA (Japan Pharmaceutical Manufacturers Association)
PMAT (The Pharmaceutical Manufactureres' Association of Tokyo)